JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1995; 25:773-780
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hird, R.
Right arrow Articles by Spinale, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hird, R.
Right arrow Articles by Spinale, F.

Differential effects of protamine sulfate on myocyte contractile function with left ventricular failure

RB Hird, FA Crawford, and FG Spinale

Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston 29425.

OBJECTIVES. This project tested two fundamental hypotheses: 1) Protamine sulfate has a direct and negative effect on myocyte contractile processes; 2) the negative effects of protamine on myocyte contractility will be enhanced in the setting of chronic left ventricular dysfunction. BACKGROUND. An increasing number of patients undergoing cardiac and vascular surgical procedures have underlying chronic left ventricular dysfunction. Protamine sulfate is commonly required during these surgical procedures but has been associated with left ventricular dysfunction. However, it is not known whether protamine may have a direct and selective effect on myocyte contractility in the setting of chronic left ventricular dysfunction. METHODS. This study examined the direct effects of protamine on isolated myocyte contractile function in 10 control pigs and 10 pigs with dilated cardiomyopathy induced by supraventricular tachycardia (rapid atrial pacing at 240 beats/min for 3 weeks). Myocyte contractile function was measured by videomicroscopy at baseline and with 10, 20, 40 or 80 micrograms/ml of protamine. In a second series of experiments, myocytes were preincubated with protamine and then stimulated with the beta-adrenergic agonist isoproterenol (25 nmol/liter). RESULTS. In the presence of 20 micrograms/ml of protamine, myocyte contractile function was unaffected in the control group but decreased by 40% from baseline values in the supraventricular tachycardia group. With 10 micrograms/ml of protamine, myocyte beta-adrenergic responsiveness was reduced by 25% in the supraventricular tachycardia group with no change in the control group. In the presence of 40 and 80 micrograms/ml of protamine, myocyte contractile function decreased in both groups. However, 40 micrograms/ml of protamine caused a more pronounced decline in myocyte function and beta-adrenergic responsiveness in the supraventricular tachycardia group. CONCLUSIONS. An increased sensitivity to the depressive effects of protamine on myocyte contractile function and beta-adrenergic responsiveness occurred in this model of chronic left ventricular dysfunction. These results suggest that patients with underlying cardiac disease may have an increased susceptibility to a sudden compromise of left ventricular contractile performance after protamine administration.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
S. E. Kimmel, M. A. Sekeres, J. A. Berlin, N. Ellison, V. J. DiSesa, and B. L. Strom
Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass
J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1916 - 1922.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1995 by the American College of Cardiology Foundation.